SPONSORED: Debunking five asthma myths as SA ranks fifth for asthma mortality globally

play article
Subscribers can listen to this article
(Image: Supplied)
(Image: Supplied)

South Africa is ranked fifth for asthma mortality in the world and with the nation’s prevalence among the highest globally, the case for better control is clear. A new awareness campaign, #yes2breathe, highlights the need to re-examine asthma treatment based on updated global recommendations overturning decades of asthma care.

The Global Initiative for Asthma (GINA) shows that poor asthma control and over-reliance on reliever inhalers – specifically the short-acting beta2 agonists (SABA) which are blue in colour, are linked to an increased risk of asthma attacks.1 GINA’s findings point toward the most significant change in asthma management in over 30 years.

Johannesburg-based GP, Doctor Marlin McKay who practices at the Goldman Medical Centre says as the prevalence in asthma climbs, so too do the myths surrounding the lung disease. He tackles the top ten asthma myths and provides guidance for those who are asthmatics, or those who care for them.

Myth 1: You cannot die from asthma       

“For those who don’t believe severe asthma can be a life-threatening illness a wakeup call should be the fact that SA ranks fifth globally for asthma mortality” says Dr McKay. He urges people to note that SA’s asthma prevalence is among the highest in the world, and adds, “we have to take action, and that starts with examining over-reliance on asthma reliever pumps.”

Myth 2: You can never be over reliant on your asthma pump

Dr McKay explains, “Many asthmatic patients use a maintenance inhaler which contains an anti-inflammatory medicine; they also use a symptom reliever inhaler which is blue in colour and contains an item which opens up the airways also known as short-acting beta2 agonists (SABA). 1,2 Asthma patients frequently underuse anti-inflammatory maintenance therapy and instead, over-rely on SABA reliever therapy which provides rapid and temporary relief. The problem with this approach is it can mask the worsening of symptoms and actually increases the risk of asthma attacks.” 3-6

Myth 3: COVID-19 increases your chances of an asthma attack

Dr McKay explains that COVID-19 can affect your nose, throat, lungs (respiratory tract) which in turn may cause an asthma attack. “We also know that an attack could possibly lead to pneumonia and acute respiratory disease, making patients vulnerable to contracting COVID-19. However, if your asthma is well controlled, and you are not over-using your reliever pumps you are no more likely to be hospitalised than patients without asthma7.” 

Myth 4: Asthma medications are habit-forming and dangerous

To debunk this myth, Dr McKay explains that it is important to distinguish between asthma reliever inhalers, “The use of SABA blue inhalers to control asthma symptoms increases the risk of asthma attacks1,8,9. Patients are recommended instead the use of a low dose inhaled corticosteroid (ICS)-formoterol therapy as needed as the preferred reliever therapy across all asthma severities,1”says Dr McKay. 

Myth 5: Asthma can be cured

Dr McKay confirms that is no cure for asthma, “It is a highly treatable disease, in fact, asthma treatments are so effective that many of my patients have near-complete control of their symptoms.”

To conclude Dr McKay adds, “Importantly, those living with - or caring for people with asthma, must separate the facts from the myths. To overturn the prevalence of asthma in South Africa let’s start with helping asthma patients assess their levels of over-reliance.”  The #yes2breathe campaign offers a first-of-its-kind digital assessment tool known as the Reliever Reliance Test. This evidence-based questionnaire will empower patients to assess their over-reliance on their blue reliever inhaler, SABA10, by answering five short questions. 

For more information about the Break Over-Reliance campaign and to take the Reliever Reliance Test, visit


  1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2020 Update. Available at: report_20_06_04-1-wms.pdf Last accessed July 2020.
  2. Burki TM. New asthma treatment recommendations. Lancet Respir Med 2019;7:479.
  3. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the asthma insights and reality in Europe (AIRE) study. Eur Respir J. 2000; 16: 802–807.
  4. Tattersfield AE, Postma DS, Barnes PJ, et al. on behalf of the FACET International Study Group. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. Am J Respir Crit Care Med. 1999; 160: 594–599.
  5. Adams RJ, Fuhlbrigge A, Guilbert T, et al. Inadequate use of asthma medication in the United States: results of the asthma in America national population survey. J Allergy Clin Immunol. 2002; 110: 58–64.
  6. Larsson, K., Kankaanranta, H., Janson, C. et al. Bringing asthma care into the twenty-first century. NPJ Prim. Care Respir. Med. 2020; 30, 25,
  7. That analysis, which looked at data from more than 1,500 patients, found that Covid-19 patients with asthma were no more likely than patients without asthma to be hospitalized. 
  8. Price D, et al. Asthma control and management in 8,000 European patients: the Recognise Asthma and Link to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014; 24: 14009.
  9. Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. Lancet. 2017; 391: 350-400.
  10. International Primary Care Respiratory Group. Blue Reliever Reliance Test. Available at: [Last accessed: July 2020]

This post and content is sponsored, written and provided by AstraZeneca.

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For only R75 per month, you have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today.
Subscribe to News24
Voting Booth
Have you entered our Health of the Nation survey?
Please select an option Oops! Something went wrong, please try again later.
33% - 9362 votes
67% - 19319 votes